Form 4: Tempus AI Director Plans $1.5M Stock Sale in Future Transaction

Tempus AI Director Theodore Leonsis reported a future sale of 20,000 Class A Common Stock shares for $1.5 million, effective August 26, 2025.

Summary

• Theodore Leonsis, a Director at Tempus AI, Inc. (TEM), reported a planned sale of 20,000 shares of Class A Common Stock.
• The transaction is scheduled to occur on August 26, 2025, at a weighted average price of $75.83 per share, totaling approximately $1,516,600.
• The sale is being conducted under a Rule 10b5-1(c) pre-arranged trading plan.
• Following this transaction, Mr. Leonsis will beneficially own 66,756 shares indirectly through the Theodore J. Leonsis Revocable Trust and 15,511 shares directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can sometimes be viewed negatively, the explicit mention of a Rule 10b5-1 plan mitigates concerns that the sale is based on negative undisclosed information. The future date of the transaction and filing is unusual but does not inherently change the neutral sentiment regarding the pre-planned nature of the sale.

Positives

• The sale is conducted under a Rule 10b5-1(c) plan, indicating it was pre-arranged and not based on immediate, non-public information, which can mitigate concerns about insider selling.
• The reported sale price of $75.83 per share is relatively high, suggesting a strong valuation for the company's stock at the time the plan was established or the transaction is set to occur.

Negatives

• A director selling a significant number of shares, even under a 10b5-1 plan, can be perceived negatively by some investors as it reduces the insider's direct stake in the company.
• The transaction date (August 26, 2025) and the filing date (August 28, 2025) are both in the future, which is highly unusual for a Form 4 that typically reports completed transactions, potentially leading to investor confusion.

Risks

• Investor perception risk: The sale by a director, even if pre-planned, might be interpreted by some investors as a lack of confidence in the company's future growth, potentially leading to negative sentiment.
• Market volatility: The actual price realized on August 26, 2025, could differ from the reported weighted average price if market conditions change significantly before the transaction date.

Industry Context

Insider sales are a routine part of public markets, often for personal financial planning. For a healthcare AI company like Tempus AI, such a transaction does not inherently reflect on broader industry trends unless it's part of a pattern across multiple executives or companies. The reported share price could indicate strong market confidence in the AI healthcare sector.

Related Party Transactions

• Theodore J. Leonsis Revocable Trust is identified as indirectly owning 66,756 shares of Class A Common Stock, which is a related party to the reporting person.

Stakeholder Impact

• Shareholders may view the director's sale with mixed feelings; some may see it as a normal part of financial planning, especially given the 10b5-1 plan, while others might interpret it as a slight reduction in insider confidence.
• Employees, customers, suppliers, and creditors are unlikely to be directly impacted by this specific insider transaction.

Key Dates

Recommendation

While a director selling shares can sometimes be a negative signal, the explicit use of a Rule 10b5-1 plan suggests the sale is for personal financial planning rather than a reaction to new, negative company-specific information. The transaction date being in the future (August 2025) and the filing date also being in the future is highly unusual and could raise questions, but without further context or clarification from the company, it's difficult to draw strong conclusions. Given the pre-planned nature, it doesn't warrant a 'sell' recommendation, but it also doesn't provide new positive catalysts for a 'buy.' Therefore, a 'hold' recommendation is appropriate, awaiting further company developments or clarification on the unusual filing dates.

Keywords

Tempus AI, TEM, Theodore Leonsis, Director, Insider Sale, Form 4, SEC Filing, 10b5-1 plan, Class A Common Stock, Equity Transaction, Healthcare AI